Mirabegron Teva

Mirabegron, the active ingredient in Mirabegron Teva, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It belongs to the therapeutic class of overactive bladder agents (ATC code G04BD12) and is used to alleviate urinary urgency, frequency and urge incontinence in adult patients with detrusor overactivity.

GNH USA supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier. The company provides the product to hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements to ensure consistent product integrity across global markets.

Mirabegron is indicated for conditions within the overactive bladder spectrum, targeting detrusor muscle activity. - Overactive bladder: improves bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the sudden need to void, enhancing daily comfort. - Urinary frequency: decreases the number of daytime voids, supporting better quality of life.

Adverse reactions reported with Mirabegron vary in frequency and severity.

Common Side Effects: - Hypertension: increase in blood pressure, often mild. - Headache: transient cranial discomfort. - Nasopharyngitis: upper respiratory tract infection symptoms. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal transit.

Serious or Rare Side Effects: - Cardiovascular events: angina, tachycardia, or arrhythmia. - Severe hypertension: marked elevation requiring medical intervention. - Urinary retention: difficulty emptying the bladder. - Allergic reactions: rash, pruritus, or angioedema. - Hepatic enzyme elevation: increased ALT/AST levels.

When prescribing Mirabegron, clinicians should consider several precautionary measures to ensure patient safety. - Blood pressure monitoring: check baseline and periodic readings due to potential hypertension. - Cardiovascular assessment: evaluate history of angina or arrhythmias before initiation. - Drug interaction review: assess concomitant use of CYP2D6 substrates that may increase plasma levels. - Renal function evaluation: adjust use in patients with severe renal impairment. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Mirabegron can alter the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase Mirabegron exposure. - Antihypertensive agents (e.g., β‑blockers, ACE inhibitors): additive blood pressure effects.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol, tramadol): may have increased plasma concentrations. - Diuretics (e.g., furosemide): potential reduction in diuretic efficacy. - Anticholinergic agents for bladder (e.g., oxybutynin): combined effect on urinary symptoms.